Redox-sensitive factors as targets of thiol compounds to hinder SARS-CoV-2 replication and inflammatory response [0.03%]
硫醇化合物通过靶向红氧还敏感因子抑制SARS-CoV-2复制和炎症反应
Marta De Angelis,Gianni Gori Savellini,Elena Piselli et al.
Marta De Angelis et al.
SARS-CoV-2 has undergone rapid genetic evolution, leading to the emergence of new variants with distinct mutations impacting global public health. Upon infection, the virus triggers a robust inflammatory response characterized by the releas...
Multilevel HierCC typing scheme for global genomic epidemiology and antimicrobial resistance surveillance of Campylobacter jejuni [0.03%]
用于全球基因组流行病学和Campylobacter jejuni抗菌药物耐药性监测的多层次HierCC分型方案
Ruochen Wu,Sandeep Kaur,Michael Payne et al.
Ruochen Wu et al.
Campylobacter jejuni is the most common bacterial cause of human gastroenteritis around the world. A stable, scalable, and standardized typing scheme is essential for epidemiological and antimicrobial resistance (AMR) surveillance for preve...
Pharmacokinetics and safety of TBAJ-587, a novel antimycobacterial diarylquinoline, in healthy participants [0.03%]
TBAJ-587（一种新型抗分枝杆菌二芳基喹啉化合物）在健康志愿者中的药代动力学和安全性研究
Jerry Nedelman,Almari Conradie,Antonio Lombardi et al.
Jerry Nedelman et al.
TBAJ-587 is a second-generation diarylquinoline with greater antimycobacterial activity and a potentially better safety profile than the first-generation bedaquiline. It is currently under development for the treatment of drug-susceptible a...
Using a liver-on-chip model to evaluate the effects of vancomycin and daptomycin on host immunometabolism and clearance of intracellular reservoirs of Staphylococcus aureus during bacteremia [0.03%]
利用肝脏芯片模型评估万古霉素和达托霉素对败血症期间宿主免疫代谢和清除金黄色葡萄球菌胞内贮存库的影响
Brent Beadell,Sujung Yi,Makayla Roberts et al.
Brent Beadell et al.
Staphylococcus aureus bacteremia (SAB) causes significant morbidity and mortality, despite treatment with guideline-recommended antibiotics. A critical contributor to SAB treatment failure is the intracellular persistence of SA within liver...
Extension of penA diversity within the genus Neisseria: characterization of a penA/ftsI homolog in Neisseria bacilliformis associated with elevated ceftriaxone MICs [0.03%]
奈瑟氏菌penA多样性的扩展：与ceftriaxone敏感性降低相关的Neisseria bacilliformis的penA/ftsI同源物的表征
Sheeba Santhini Manoharan-Basil,Tessa de Block,Izumo Kanesaka et al.
Sheeba Santhini Manoharan-Basil et al.
Reduced susceptibility to extended-spectrum cephalosporins in Neisseria gonorrhoeae is primarily mediated by structural alterations in penicillin-binding protein 2 (PBP2), encoded by penA, frequently arising through interspecies recombinati...
Trifluoperazine exhibits broad-spectrum antiviral activity against arboviruses [0.03%]
三氟拉嗪具有广谱抗虫媒病毒活性
Laxmi Mishra,Manjula Kalia
Laxmi Mishra
The recurrent outbreaks and geographical expansion of mosquito-borne arboviruses pose a significant challenge to public health worldwide. The disease outcome for arboviral infections ranges from acute febrile illness to severe conditions su...
Physiologically based pharmacokinetic (PBPK) model to predict the magnitude of drug-drug interaction between vincristine and the azole antifungals isavuconazole, posaconazole, and voriconazole in children [0.03%]
基于生理的药代动力学(PBPK)模型预测长春新碱与伏西康唑、泊沙康唑和伏立康唑在儿童中的药物相互作用大小
Mary P Choules,Amit Desai,Laura Lynn Kovanda et al.
Mary P Choules et al.
Invasive fungal diseases (IFDs), including invasive aspergillosis (IA) and invasive mucormycosis (IM), occur primarily in immunocompromised and/or hospitalized patients and are associated with increased morbidity and mortality. Isavuconazol...
Selective digestive decontamination and antimicrobial resistance: defining thresholds before global implementation [0.03%]
选择性消化道去污染与抗菌素耐药性：全球实施前的阈值研究
Shubhendu Bajpai,Abdullah Sultany,Kevin Carroll et al.
Shubhendu Bajpai et al.
Reply to Bajpai et al., "Selective digestive decontamination and antimicrobial resistance: defining thresholds before global implementation" [0.03%]
对Bajpai等关于“消化道选择性消毒与抗菌药物耐药性：全球实施前界定阈值”的回复
Wanda Cornistein,Maria Inés Staneloni;PREVAR Study Group
Wanda Cornistein
Pharmacokinetics of injectable favipiravir: phase I, randomized, double-blind, placebo-controlled study in healthy East Asian subjects [0.03%]
注射用法维拉韦的药代动力学：健康东亚受试者中的I期随机双盲安慰剂对照研究
Hiroshige Mikamo,Masahiro Nakabayashi,Tsutomu Sakurai
Hiroshige Mikamo
Favipiravir, an oral antiviral medication, has been approved in Japan for the treatment of patients with novel or re-emerging influenza and severe fever with thrombocytopenia syndrome (SFTS). Randomized, double-blind, placebo-controlled tri...